Harmony Biosciences Announces Poster Presentation at the 17th European Narcolepsy Days
Harmony Biosciences (Nasdaq: HRMY) announced it will present a poster at the 17th European Narcolepsy Days, detailing information from its ongoing Phase 3 trials of HBS-301. The poster will cover the ONSTRIDE-1 study for narcolepsy and ONSTRIDE-2 for idiopathic hypersomnia. HBS-301 is an investigational, high-dose formulation of pitolisant tablets being developed to treat excessive daytime sleepiness in patients with narcolepsy or idiopathic hypersomnia.
A drug being tested for two sleep disorders will be presented in Bern
Harmony Biosciences (Nasdaq: HRMY) will present a poster on its ongoing HBS-301 Phase 3 trials at the 17th European Narcolepsy Days in Bern, Switzerland, on October 2–3, 2026. HBS-301 is an investigational, optimized, high-dose formulation of enteric-coated pitolisant tablets being developed to treat excessive daytime sleepiness and other symptoms in patients with narcolepsy and idiopathic hypersomnia. The poster presentation will cover both the ONSTRIDE-1 study in adults with narcolepsy and the ONSTRIDE-2 study in adults with idiopathic hypersomnia, both of which are randomized, double-blind, and placebo-controlled.
Oppenheimer Reiterates Outperform Rating on Harmony Biosciences Holdings Inc. (HRMY)
Oppenheimer analyst Andreas Argyrides has reiterated an Outperform rating for Harmony Biosciences Holdings Inc. (NASDAQ: HRMY). The firm also maintained a $70.00 price target for the company's stock. The full analyst report is available to premium subscribers.
Harmony Biosciences stock rises as acquisition plans take shape
Harmony Biosciences stock (HRMY) rose 12.7% year-to-date, closing at $42.18 on September 22, 2026, as the company explores acquisition opportunities for inorganic growth. Analysts maintain a consensus price target of $47.11 with a "Hold" rating, reflecting a balanced outlook on its valuation in light of potential strategic expansion. The company, focused on rare neurological disorders, holds a market capitalization of $2.45 billion and a trailing P/E ratio of 13.67.
Officer stock sale at Harmony Biosciences (NASDAQ: HRMY) follows earlier 10b5-1 trades
An officer at Harmony Biosciences (HRMY), Kumar Budur, has filed a Rule 144 notice to sell 1,800 shares of common stock after exercising stock options on September 16, 2026. This proposed sale, with an aggregate market value of $75,906.00, follows several prior Rule 10b5-1 sales made by Budur in early September 2026, totaling over 33,954 shares with significant proceeds. The filing provides transparency into insider trading activities and the process for selling restricted securities.
Harmony Biosciences CMO sells $1.65m in shares
Harmony Biosciences' Chief Medical Officer, Budur Kumar, sold approximately $1.65 million worth of company shares through a Rule 10b5-1 trading plan between September 16-18, 2026. Concurrently, Mr. Kumar acquired 38,452 shares by exercising stock options valued at about $1.17 million. These transactions occurred as the stock traded near its 52-week high, following strong recent performance and positive analyst coverage.
$1.5M stock sale planned by Harmony Biosciences (NASDAQ: HRMY) officer
Kumar Budur, an officer at Harmony Biosciences Holdings, Inc. (HRMY), has filed a Form 144 notice indicating a proposed resale of 35,852 common stock shares, valued at approximately $1.5 million. This sale is scheduled for September 18, 2026, following the exercise of stock options. Budur has also made several Rule 10b5-1 plan sales throughout September 2026.
Harmony Biosciences (HRMY) CMO exercises options and sells shares
Harmony Biosciences' Chief Medical Officer, Kumar Budur, exercised stock options for 38,452 shares and subsequently sold the same number of shares under a Rule 10b5-1 trading plan. The transactions, which occurred between September 16-18, 2026, involved exercising options at prices around $30.27-$30.69 and selling shares at weighted average prices near $43. The net effect of these transactions was a sale of 38,452 shares.
Harmony Biosciences Holdings, Inc. - Common Stock (Nasdaq:HRMY) Price Chart
This article provides real-time streaming delayed price information for Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY). It shows the stock price at 41.53, unchanged, as of 4:00 PM EDT, Sep 22, 2026. The page also offers various financial tools and data, including detailed quotes, charting, historical prices, news, and research.
After preset plan trades, Harmony Biosciences (NASDAQ: HRMY) officer plans 800-share sale
Kumar Budur, an officer at Harmony Biosciences (HRMY), has filed a Rule 144 notice to sell 800 shares of common stock on September 17, 2026, following the exercise of stock options. The proposed sale has an aggregate market value of approximately $33,768. This filing also discloses previous Rule 10b5-1 plan sales made by Budur in the past three months, totaling several blocks of shares.
Engaging In Options Activity, Kumar Budur Exercises Options Valued At $262K In Harmony Biosciences Hldgs
Kumar Budur, Chief Medical Officer at Harmony Biosciences Hldgs (NASDAQ: HRMY), exercised stock options for 22,954 shares valued at $262,978, with an exercise price of $30.49 per share. Harmony Biosciences is a pharmaceutical company focused on rare neurological diseases, with its product WAKIX for narcolepsy. The company reported strong financial metrics including 30.32% revenue growth, a 75.81% gross margin, and a low P/E ratio of 13.47, suggesting potential undervaluation.
Harmony Biosciences (NASDAQ: HRMY) CMO exercises 22,954 options, sells shares under trading plan
Harmony Biosciences' Chief Medical Officer, Kumar Budur, exercised stock options for 22,954 shares at prices between $30.27 and $30.69 on September 8, 2026. Concurrently, he sold a total of 33,954 shares in open-market transactions on September 4 and 8, 2026, at weighted average prices ranging from $41.51 to $43.20. These sales were conducted under a Rule 10b5-1 trading plan.
Harmony Biosciences (HRMY) executive to sell about $230K in stock
An executive at Harmony Biosciences (HRMY), Kumar Budur, has filed a Rule 144 notice to sell 5,500 shares of common stock, valued at approximately $230,230. These shares were acquired through the vesting of restricted stock units between January 24, 2025, and January 25, 2026. The proposed sale will be executed through Morgan Stanley Smith Barney.
Why Is Harmony Biosciences (HRMY) Up 12.1% Since Last Earnings Report?
Harmony Biosciences (HRMY) shares have increased by 12.1% since its last earnings report, driven by strong Q2 2026 results where earnings and revenues surpassed estimates, largely due to demand for its lead drug, Wakix. The company also provided positive pipeline updates for BP-205 and pitolisant, maintaining its 2026 revenue guidance for Wakix at $1 billion to $1.04 billion. Analyst estimates for the stock have trended upward, and Harmony Biosciences currently holds a Zacks Rank #3 (Hold).
Harmony Biosciences Announces Poster Presentations at the 16th European Epilepsy Congress
Harmony Biosciences announced it will present encore data on EPX-100 (clemizole hydrochloride) at the 16th European Epilepsy Congress. EPX-100 is being investigated for Dravet syndrome and Lennox-Gastaut syndrome in the ongoing ARGUS and LIGHTHOUSE trials. The presentations will include preliminary results from the open-label extension phase of the ARGUS study and a drug-drug interaction study.
Harmony Biosciences Announces Poster Presentations at the 16th European Epilepsy Congress
Harmony Biosciences (Nasdaq: HRMY) will present encore data on EPX-100 (clemizole hydrochloride) at the 16th European Epilepsy Congress in Athens, Greece. EPX-100 is being investigated for Dravet syndrome and Lennox-Gastaut syndrome in the ARGUS and LIGHTHOUSE trials. The presentations will cover preliminary results from the open-label extension phase of the ARGUS study and a drug-drug interaction study of EPX-100.
Harmony Biosciences stock hits 52-week high at $42.70
Harmony Biosciences (HRMY) stock has reached a new 52-week high of $42.70, reflecting a 13.59% positive change over the past year and a 43% return in the last six months. InvestingPro analysis suggests the stock is undervalued with a fair value of $59.06 and an "EXCELLENT" financial health score. The company recently surpassed Q2 2026 earnings expectations with record Wakix revenue, and analysts predict continued profitability, despite ongoing intellectual property litigation and competition.
Harmony Biosciences stock hits 52-week high at $42.70 By Investing.com
Harmony Biosciences (HRMY) stock reached a new 52-week high of $42.70, with a market capitalization of $2.49 billion, driven by a 43% six-month return. InvestingPro analysis suggests the stock is undervalued with a fair value of $59.06 and holds an "EXCELLENT" financial health score. The company reported strong Q2 2026 earnings, surpassing expectations with $1.28 adjusted profit per share and record net revenue from its Wakix product, and analysts predict continued profitability.
Harmony Biosciences to Participate in 2026 Cantor Global Healthcare Conference
Harmony Biosciences Holdings, Inc. announced its management team will participate in a fireside chat at the 2026 Cantor Global Healthcare Conference on September 10, 2026, at 10:20 a.m. E.T. A webcast of the event will be available on the company's investor relations website. Harmony Biosciences focuses on developing innovative therapies for rare neurological diseases.
Harmony Biosciences to Participate in 2026 Cantor Global Healthcare Conference
Harmony Biosciences Holdings, Inc. announced its management team will participate in a fireside chat at the 2026 Cantor Global Healthcare Conference on Thursday, September 10, 2026, at 10:20 a.m. E.T. A webcast of the event will be available on the company's investor relations website. Harmony Biosciences is a pharmaceutical company focused on developing therapies for rare neurological diseases.
Harmony Biosciences to Participate in 2026 Cantor Global Healthcare Conference
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) announced that its management team will participate in a fireside chat at the 2026 Cantor Global Healthcare Conference on September 10, 2026, at 10:20 a.m. E.T. A webcast of the event will be available on the investor page of the company's website. Harmony Biosciences is a pharmaceutical company focused on developing therapies for rare neurological diseases.
Wolfe Research initiates Harmony Biosciences stock at Outperform
Wolfe Research has initiated coverage on Harmony Biosciences (NASDAQ:HRMY) with an Outperform rating and a $60 price target, citing significant upside potential and the resilience of its Wakix franchise. Despite ongoing IP litigation, Wakix is projected to reach $1 billion in sales in 2026, with new formulations expected to extend IP protection into the 2040s. The firm also anticipates future upside from BP-205, with important data readouts expected in late 2026 and early 2027.
Tieton Capital Management LLC Takes Position in Harmony Biosciences Holdings, Inc. $HRMY
Tieton Capital Management LLC has acquired a new position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) during the second quarter, purchasing 306,781 shares valued at approximately $11.17 million. This investment makes Harmony Biosciences the 16th largest holding in Tieton Capital Management LLC's portfolio, representing 3.2% of its total assets. Other institutional investors have also adjusted their stakes in Harmony Biosciences, and the company has received mixed analyst ratings with an average "Hold" rating and a price target of $45.50.
Denali Advisors LLC Purchases 29,700 Shares of Harmony Biosciences Holdings, Inc. $HRMY
Denali Advisors LLC has significantly increased its stake in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by purchasing an additional 29,700 shares, bringing its total holdings to 89,600 shares valued at approximately $3.26 million. This move comes as Harmony Biosciences reported strong quarterly earnings, surpassing analyst expectations with $1.28 EPS and $261.28 million in revenue. Despite a consensus "Hold" rating from analysts, the company's stock shows positive momentum, with institutional investors collectively owning a substantial 86.23% of the company.
Aurora Investment Counsel Invests $2.37 Million in Harmony Biosciences Holdings, Inc. $HRMY
Aurora Investment Counsel has acquired a new position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY), purchasing 65,148 shares valued at approximately $2.37 million, making it their 22nd largest holding. Other institutional investors have also adjusted their stakes in Harmony Biosciences. The company's stock recently increased by 2.8%, and analysts have issued various ratings, with the consensus being a "Hold" with a target price of $45.50.
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Given Consensus Recommendation of "Hold" by Analysts
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) has received a consensus "Hold" rating from ten analysts, with an average 12-month price target of $45.50. The company recently surpassed earnings and revenue expectations, reporting $1.28 adjusted EPS against an estimated $0.96 and a 30.3% year-over-year revenue increase to $261.28 million. Institutional investors hold a significant 86.23% stake in HRMY, with several firms increasing their positions.
Did Strong Q2 Earnings and Completed Buybacks Just Shift Harmony Biosciences' (HRMY) Investment Narrative?
Harmony Biosciences (HRMY) reported strong Q2 2026 earnings, with net income of US$75.43 million and diluted EPS of US$1.28, and completed a US$50 million share repurchase program. While these results reinforce the company's profitability, the core investment narrative remains largely unchanged, with a continued reliance on its flagship drug WAKIX and the need for pipeline diversification. The earnings beat may lead analysts to reassess more pessimistic revenue and earnings forecasts, and the company projects significant revenue and earnings growth by 2028.
Did Strong Q2 Earnings and Completed Buybacks Just Shift Harmony Biosciences' (HRMY) Investment Narrative?
Harmony Biosciences (HRMY) reported strong Q2 2026 earnings, with net income of US$75.43 million and diluted EPS of US$1.28, and completed a US$50 million share repurchase program. While this reinforces the company's profitability, its investment narrative still hinges on broadening beyond its flagship drug WAKIX and mitigating the risk of concentration on a single product. Forecasts project significant revenue and earnings growth by 2028, suggesting a potential 24% upside from its current price.
Chase Investment Counsel Corp Takes $1.82 Million Position in Harmony Biosciences Holdings, Inc. $HRMY
Chase Investment Counsel Corp has acquired a new position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY), purchasing 50,000 shares valued at approximately $1.82 million, representing a 0.09% stake. Harmony Biosciences reported strong quarterly earnings of $1.28 per share, exceeding estimates, with revenue increasing by 30.3% year over year. Despite mixed analyst ratings, with an average "Hold" and a price target of $45.50, the company's stock shows solid financial metrics and institutional ownership.
Harmony Biosciences (NASDAQ:HRMY) Rating Increased to Strong-Buy at Wall Street Zen
Wall Street Zen has upgraded Harmony Biosciences (NASDAQ:HRMY) from a "buy" to a "strong-buy" rating. This upgrade comes as the company reported strong quarterly earnings, beating analyst estimates with an EPS of $1.28 and a 30.3% year-over-year revenue increase to $261.28 million. Despite this, the broader analyst consensus for HRMY remains a "hold" with an average target price of $45.50.
Harmony Biosciences Highlights Record WAKIX Growth, Advances Orexin and Epilepsy Pipeline
Harmony Biosciences reported record quarterly performance for its narcolepsy treatment WAKIX, supporting further investment in its pipeline. The company provided updates on its orexin 2 receptor agonist BP-205 for narcolepsy and other CNS indications, and EPX-100 (clemizole hydrochloride) for Dravet and Lennox-Gastaut syndromes, with key data readouts and potential approvals expected in the coming years. Additionally, Harmony outlined plans for new formulations of pitolisant (WAKIX), including a gastro-resistant version and a higher-dose option, aiming to expand treatment options and market exclusivity.
Harmony Biosciences Highlights Record WAKIX Growth, Advances Orexin and Epilepsy Pipeline
Harmony Biosciences reported record quarterly growth for its narcolepsy treatment WAKIX, which supports further investment in its pipeline. The company is advancing BP-205, an orexin 2 receptor agonist, with promising early data and plans for multiple Phase II studies. Additionally, Harmony is progressing Phase III trials for EPX-100 in Dravet and Lennox-Gastaut syndromes, and developing new pitolisant formulations to expand treatment options for narcolepsy and idiopathic hypersomnia.
Zacks Research Downgrades Harmony Biosciences (NASDAQ:HRMY) to Hold
Zacks Research has downgraded Harmony Biosciences (NASDAQ:HRMY) from a "strong buy" to a "hold" rating, aligning with the overall consensus. Despite the downgrade, Harmony Biosciences reported a strong quarter with EPS of $1.28 and revenue of $261.28 million, exceeding analyst expectations. The stock opened at $39.77, near its 52-week high, and institutional investors hold a significant 86.23% stake in the company.
Why Harmony Biosciences (HRMY) Is Up 9.0% After Q2 Earnings Surge And Pipeline Progress
Harmony Biosciences (HRMY) saw its stock rise by 9.0% following a strong Q2 2026 earnings report, with net income and EPS significantly increasing year-over-year. The company reaffirmed its 2026 net product revenue guidance, indicating confidence in its lead drug WAKIX while it continues to advance its neurology pipeline. Despite the positive results, the article highlights the ongoing concentration risk associated with WAKIX and the need for pipeline diversification.
Why Harmony Biosciences (HRMY) Is Up 9.0% After Q2 Earnings Surge And Pipeline Progress
Harmony Biosciences reported a significant 9.0% stock increase after its Q2 2026 earnings surged to US$75.43 million, with basic EPS rising to US$1.30. This strong performance, alongside pipeline progress in rare neurological diseases, reinforces the company's near-term outlook and its reliance on WAKIX revenue while its new therapies mature. The company reiterated its 2026 net product revenue guidance of US$1.0 billion to US$1.04 billion, prompting investors to consider the balance between current cash generation and the concentration risk around its primary drug.
Harmony Biosciences (NASDAQ:HRMY) Upgraded by Wall Street Zen to "Buy" Rating
Wall Street Zen has upgraded Harmony Biosciences (NASDAQ:HRMY) from a "hold" to a "buy" rating. The company recently reported strong quarterly earnings of $1.28 per share, surpassing estimates, with revenue increasing by 30.3% year-over-year to $261.28 million. Institutional investors hold a significant 86.23% of the shares, with BlackRock Inc. notably establishing a new position worth approximately $258.6 million.
First Trust Advisors LP Sells 50,805 Shares of Harmony Biosciences Holdings, Inc. $HRMY
First Trust Advisors LP reduced its stake in Harmony Biosciences Holdings, Inc. by 32.7% during the first quarter, selling 50,805 shares and retaining 104,549 shares valued at approximately $2.93 million. Harmony Biosciences reported strong quarterly earnings, beating analyst estimates with an EPS of $1.28 and a 30.3% year-over-year revenue increase to $261.28 million. Despite varied analyst ratings, the company holds a "Moderate Buy" consensus with an average price target of $45.50.
Harmony Biosciences Holdings (HRMY) Could Be 19% Undervalued On Strong Q2 Earnings
Harmony Biosciences Holdings (HRMY) has shown strong performance following its Q2 2026 earnings, with increased net income and EPS, supported by WAKIX and pipeline updates. The company's share price has gained significantly over the past 90 days, and a valuation narrative suggests it is 19.2% undervalued, with a fair value of $47.30 per share. This positive outlook is driven by anticipated faster earnings growth, higher profitability, and a promising late-stage pipeline including potential first-to-market launches.
Harmony Biosciences (NASDAQ: HRMY) holder to sell 700,883 shares
VALOR IV PHARMA HOLDINGS LLC, a shareholder of Harmony Biosciences (NASDAQ: HRMY), has filed to sell up to 700,883 shares of common stock. These shares, with an aggregate market value of $26,563,465.70, were originally acquired in 2017 through a private acquisition. The filing also notes prior sales by the same holder totaling 116,490 shares for approximately $4.3 million over the past three months.
Harmony Biosciences (HRMY) Is Up 9.0% After Q2 Earnings Jump And Pipeline Progress - What's Changed
Harmony Biosciences (HRMY) reported a significant increase in Q2 2026 net income, rising to US$75.43 million from US$39.78 million a year prior, with EPS increasing to US$1.30. The company also announced progress in its neurology pipeline and clinical trials, which strengthens its investment narrative by balancing current cash-generating products with long-term development assets. While the earnings jump is positive, the company's heavy reliance on its drug WAKIX remains a key risk for investors.
Harmony Biosciences Holdings, Inc. Just Recorded A 34% EPS Beat: Here's What Analysts Are Forecasting Next
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) reported a significant 34% EPS beat for its second quarter, with revenue also exceeding expectations. Analysts have revised their future earnings estimates upwards, projecting robust growth in the coming years. Despite these positive revisions, there are concerns regarding the company's P/E ratio relative to its industry and the broader market.
Harmony Biosciences to Participate in Piper Sandler Virtual CNS Symposium
Harmony Biosciences will participate in a fireside chat at the Piper Sandler Virtual CNS Symposium on Thursday, August 13, 2026, at 1:30 p.m. ET. A webcast of the event will be available on the investor page of the company's website. Harmony Biosciences focuses on developing innovative therapies for rare neurological diseases.
Harmony Biosciences management plans Aug. 13 fireside chat webcast
Harmony Biosciences (Nasdaq: HRMY) announced that its management team will participate in a fireside chat at the Piper Sandler Virtual CNS Symposium on Thursday, August 13, 2026, at 1:30 p.m. ET. A live webcast will be accessible via the investor page of the Harmony Biosciences website. The company is focused on developing and commercializing therapies for patients with rare neurological diseases.
Analysts Are Bullish on These Healthcare Stocks: Harmony Biosciences Holdings (HRMY), Beam Therapeutics (BEAM)
Two healthcare stocks, Harmony Biosciences Holdings (HRMY) and Beam Therapeutics (BEAM), have received bullish ratings from analysts. H.C. Wainwright reiterated a Buy rating for Harmony Biosciences with a $55.00 price target, while Beam Therapeutics holds a Strong Buy consensus with a target of $55.00, suggesting significant upside. These recommendations highlight analyst confidence in the future performance of these companies within the healthcare sector.
Harmony Biosciences Holdings, Inc. Stock 12‑Month Price Target Cut to $44.7, Implies 26% Upside
Harmony Biosciences Holdings, Inc.'s average 12-month stock price target has been reduced from $45.5 to $44.7 by 10 analysts, with individual forecasts ranging from $28 to $70 per share. This new target suggests a potential upside of approximately 26% based on the August 3rd closing price. Despite the target cut, the consensus rating from covering analysts remains a "Buy."
Harmony Biosciences (HRMY) Q2 2026 earnings summary
Harmony Biosciences (HRMY) reported record Q2 2026 net revenue of $261.3 million, a 30% increase year-over-year, driven by strong WAKIX demand. The company reiterated its full-year 2026 net revenue guidance of $1.0 billion to $1.04 billion and advanced its pipeline with positive Phase 1 data for BP-205 and other late-stage CNS programs. Harmony Biosciences maintains a robust pipeline with five phase III registration studies and significant liquidity.
Harmony Biosciences 2Q 2026: Revenue $261.28M, EPS $1.28— 10-Q Summary
Harmony Biosciences Holdings, Inc. reported strong second-quarter 2026 results, with revenue reaching $261.28 million and diluted EPS at $1.28, significantly up from the prior year. This growth was driven by increased product volume and a price adjustment in January 2026. The company also highlighted expanded formulary coverage, progress in its product pipeline with an NDA submitted for Pitolisant GR, and active IP and licensing efforts.
Harmony Biosciences Holdings, Inc. Q2 2026 Earnings Call Summary
Harmony Biosciences Holdings, Inc. reported record Q2 2026 net revenue of $261.3 million for WAKIX, a 30% year-over-year increase, and reaffirmed full-year guidance of $1 billion to $1.04 billion. The company highlighted promising Phase I data for its new orexin-2 receptor agonist, BP-205, with multiple catalysts expected, and detailed its strategic financial position with $962.5 million in cash for potential M&A. Operational challenges include increased cost of sales due to new royalty obligations and ongoing litigation with an ANDA filer, AET Pharma.
Harmony Biosciences Holdings Inc. (HRMY) PT Lowered to $70 at Oppenheimer
Oppenheimer analyst Andreas Argyrides has lowered the price target for Harmony Biosciences Holdings Inc. (HRMY) to $70. This information was updated on August 4, 2026, at 2:30 PM EDT. The full details of this analyst action are available only to premium subscribers of StreetInsider.com.
Oppenheimer lowers Harmony Biosciences stock price target on model updates
Oppenheimer has lowered its price target for Harmony Biosciences Holdings Inc. (NASDAQ:HRMY) to $70 from $85, while maintaining an Outperform rating. This adjustment follows the company's strong second-quarter 2026 results, which saw Wakix net sales exceed estimates, and the reiteration of full-year 2026 guidance. The firm's model update also considers new Phase 1 data for BP-205 and upcoming intellectual property resolution for Wakix.
